SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German
SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German Breast Group presented at the 2012 San Antonio Breast Cancer Symposium. Professor Sibylle Loibl from Frankfurt University told Peter Goodwin about findings from their analysis of eight German neoadjuvant studies.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/121218SibylleLoiblPODCASTLoRes.mp3]